Eterna Therapeutics Inc. (ERNA)

NASDAQ: ERNA · IEX Real-Time Price · USD
3.36
+0.09 (2.75%)
At close: Dec 1, 2022 4:00 PM
3.32
-0.04 (-1.19%)
After-hours: Dec 1, 2022 5:11 PM EST
2.75%
Market Cap 12.04M
Revenue (ttm) n/a
Net Income (ttm) -28.81M
Shares Out 2.94M
EPS (ttm) -2.83
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 7,853
Open 3.3
Previous Close 3.27
Day's Range 3.24 - 3.46
52-Week Range 2.74 - 127.6
Beta n/a
Analysts Sell
Price Target n/a
Earnings Date Nov 15, 2022

About ERNA

Brooklyn ImmunoTherapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Its advanced program is IRX-2 that is in a Phase 2b clinical trial in patients with squamous cell cancer of the head and neck. The company also develops therapies using gene-editing and cell therapy technology for the treatment of oncology, blood disorder, and monogenic disease. Brooklyn ImmunoTherapeutics, Inc. is based in Brooklyn, New York. [Read more]

Industry Biotechnology
Founded 2018
Employees 10
Stock Exchange NASDAQ
Ticker Symbol ERNA
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

No stock price forecast available yet.

Price Target
n/a
Analyst Consensus: Sell
Stock Forecasts

News

Eterna Therapeutics Announces Research Collaboration to Develop Advanced Gene-Edited iPS Cell Therapies

SAN DIEGO, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”), a biopharmaceutical company using advanced cell engineering technology to develop transf...

1 month ago - GlobeNewsWire

Eterna Therapeutics to Present at iPSC-Derived Immunotherapies Congress

SAN DIEGO, Oct. 18, 2022 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”), a biopharmaceutical company using advanced cell engineering technology to develop transf...

1 month ago - GlobeNewsWire

Eterna Therapeutics Completes Name Change, Acquires Option to License iPSC-Derived NK and T Cell Therapies from Exaci...

The Eterna corporate mission is to realize the potential of cell engineering to provide patients with transformational new medicines

1 month ago - GlobeNewsWire

Brooklyn ImmunoTherapeutic changing name to Eterna Therapeutics on Monday

Brooklyn ImmunoTherapeutics Inc. said Tuesday it'll change its stock trading ticker to ERNA on Monday, Oct. 17, as part of a name change to Eterna Therapeutics Inc. The San Diego-based clinical stage bi...

1 month ago - Market Watch

Brooklyn ImmunoTherapeutics Announces Name Change to Eterna Therapeutics and Provides Corporate Updates

New name reflects Company focus on leveraging exclusively in-licensed foundational mRNA cell engineering patent portfolio

1 month ago - GlobeNewsWire

Brooklyn ImmunoTherapeutics Announces Results of Phase 2 Study of IRX-2 in Head and Neck Cancer

SAN DIEGO, July 26, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (Nasdaq:BTX) (“Brooklyn” or the “Company”) today announces results from the INSPIRE phase 2 trial of IRX-2, a multi-cytokin...

4 months ago - GlobeNewsWire

Brooklyn ImmunoTherapeutics Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency

SAN DIEGO, June 17, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (Nasdaq:BTX) (“Brooklyn” or the “Company”), a biopharmaceutical company focused on developing advanced therapies using stat...

5 months ago - GlobeNewsWire

Brooklyn ImmunoTherapeutics Announces Board Changes

SAN DIEGO, June 07, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (Nasdaq:BTX) (“Brooklyn” or the “Company”), a biopharmaceutical company focused on exploring the role that cytokine, gene e...

5 months ago - GlobeNewsWire

Brooklyn ImmunoTherapeutics Announces Changes to Executive Management: Matt Angel, Ph.D. Appointed Interim Chief Exec...

SAN DIEGO, May 31, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (Nasdaq:BTX) (“Brooklyn” or the “Company”), a biopharmaceutical company focused on exploring the role that cytokine, gene ed...

6 months ago - GlobeNewsWire

Brooklyn ImmunoTherapeutics Announces Receipt of Notice from Nasdaq Regarding Delayed Filing of Quarterly Report on F...

SAN DIEGO, May 27, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (Nasdaq:BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine, gene editing, and cell t...

6 months ago - GlobeNewsWire

Brooklyn ImmunoTherapeutics Announces Establishment of New Research and Development Facility for Advancement of Engin...

Company has expanded team with scientific hires who hold research expertise in stem cells, synthetic RNA, nanoparticle delivery systems and immunology Company has expanded team with scientific hires who...

7 months ago - GlobeNewsWire

Brooklyn ImmunoTherapeutics Announces Fourth Quarter and Full Year 2021 Financial Results

SAN DIEGO, April 15, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (Nasdaq:BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine, gene editing, and cell...

7 months ago - GlobeNewsWire

Brooklyn ImmunoTherapeutics Announces Closing of $12 Million Private Placement

NEW YORK, March 09, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (Nasdaq: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine, and gene editing/cell ...

8 months ago - GlobeNewsWire

Brooklyn ImmunoTherapeutics Welcomes Erin S. Enright and Heather B.

NEW YORK, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc . (Nasdaq: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell t...

10 months ago - GlobeNewsWire

Brooklyn ImmunoTherapeutics Provides Update on Regenerative Medicine Intellectual Property Portfolio

NEW YORK, Jan. 13, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc . (Nasdaq: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine, gene editing, and cell...

10 months ago - GlobeNewsWire

Brooklyn ImmunoTherapeutics Added to ICE Biotechnology Index

NEW YORK, Dec. 17, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc . (Nasdaq: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell t...

11 months ago - GlobeNewsWire

Brooklyn ImmunoTherapeutics Named to Nasdaq Biotechnology Index

NEW YORK, Dec. 14, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc . (Nasdaq: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell t...

11 months ago - GlobeNewsWire

Brooklyn ImmunoTherapeutics to Present at Two Upcoming December Conferences

NEW YORK, Dec. 02, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc . (Nasdaq: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell t...

11 months ago - GlobeNewsWire

Brooklyn ImmunoTherapeutics Welcomes Susan McClatchey as Vice President and Head of Quality

Company Continues to Secure Resources to Build Gene Editing/Cell Therapy Drug Development Platform Company Continues to Secure Resources to Build Gene Editing/Cell Therapy Drug Development Platform

1 year ago - GlobeNewsWire

Brooklyn ImmunoTherapeutics Announces Filing of Registration Statement for Proposed Secondary Offering of Shares Issu...

NEW YORK, Nov. 19, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (Nasdaq: BTX) (“Brooklyn”) today announced that on November 18, 2021 it filed with the Securities and Exchange Commission a ...

1 year ago - GlobeNewsWire

Brooklyn ImmunoTherapeutics Announces Third Quarter 2021 Financial Results

NEW YORK, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (Nasdaq:BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine, gene editing, and cell t...

1 year ago - GlobeNewsWire

Brooklyn ImmunoTherapeutics to Move Stock Exchange Listing to Nasdaq

Ticker Symbol to Remain “BTX” Ticker Symbol to Remain “BTX”

1 year ago - GlobeNewsWire

Brooklyn ImmunoTherapeutics Reports Inducement Grants

NEW YORK, Sept. 23, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene editing...

1 year ago - GlobeNewsWire

Brooklyn ImmunoTherapeutics Appoints Roger Sidhu, M.D. as Chief Medical Officer

NEW YORK, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc . (NYSE American: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene editin...

1 year ago - GlobeNewsWire

Brooklyn ImmunoTherapeutics Provides Highlights of Shareholder Update Call from September 20, 2021

NEW YORK, Sept. 21, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene editing...

1 year ago - GlobeNewsWire